Cargando…
PT578. Endothelial-monocyte-activating polypeptide-2 (EMAP-2) may be a novel treatment target of Alzheimer’s disease
Autores principales: | Jang, Sooah, Jeong, Jihyeon, Kim, Eosu, Kim, Chul Hoon, Namkoong, Kee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5616912/ http://dx.doi.org/10.1093/ijnp/pyw044.578 |
Ejemplares similares
-
Autophagy Induction by Endothelial-Monocyte Activating Polypeptide II Contributes to the Inhibition of Malignant Biological Behaviors by the Combination of EMAP II with Rapamycin in Human Glioblastoma
por: Ma, Jun, et al.
Publicado: (2015) -
Long-Term Culture of Organotypic Hippocampal Slice from Old 3xTg-AD Mouse: An ex vivo Model of Alzheimer’s Disease
por: Jang, Sooah, et al.
Publicado: (2018) -
MiR-429 Regulated by Endothelial Monocyte Activating Polypeptide-II (EMAP-II) Influences Blood-Tumor Barrier Permeability by Inhibiting the Expressions of ZO-1, Occludin and Claudin-5
por: Chen, Liangyu, et al.
Publicado: (2018) -
Epitope-preserving magnified analysis of proteome (eMAP)
por: Park, Joha, et al.
Publicado: (2021) -
FTY720 attenuates accumulation of EMAP-II(+) and MHC-II(+) monocytes in early lesions of rat traumatic brain injury
por: Zhang, Zhiyuan, et al.
Publicado: (2007)